CTLA4 and neoplasm: As a result of over a century’s efforts to understand the role of the immune system in controlling cancer, immunomodulation by checkpoint inhibitors (targeting both CTLA-4 and the PD-1/PD-L1 axis) induced a durable tumor response in a wide range of malignancies.